These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 23420304)

  • 1. Bevacizumab treatment before resection of colorectal liver metastases: safety, recovery of liver function, pathologic assessment.
    Dede K; Mersich T; Besznyák I; Zaránd A; Salamon F; Baranyai ZS; Landherr L; Jakab F; Bursics A
    Pathol Oncol Res; 2013 Jul; 19(3):501-8. PubMed ID: 23420304
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Perioperative complications after neoadjuvant chemotherapy with and without bevacizumab for colorectal liver metastases.
    Lubezky N; Winograd E; Papoulas M; Lahat G; Shacham-Shmueli E; Geva R; Nakache R; Klausner J; Ben-Haim M
    J Gastrointest Surg; 2013 Mar; 17(3):527-32. PubMed ID: 23299220
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Extended preoperative chemotherapy does not improve pathologic response and increases postoperative liver insufficiency after hepatic resection for colorectal liver metastases.
    Kishi Y; Zorzi D; Contreras CM; Maru DM; Kopetz S; Ribero D; Motta M; Ravarino N; Risio M; Curley SA; Abdalla EK; Capussotti L; Vauthey JN
    Ann Surg Oncol; 2010 Nov; 17(11):2870-6. PubMed ID: 20567921
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor progression while on chemotherapy: a contraindication to liver resection for multiple colorectal metastases?
    Adam R; Pascal G; Castaing D; Azoulay D; Delvart V; Paule B; Levi F; Bismuth H
    Ann Surg; 2004 Dec; 240(6):1052-61; discussion 1061-4. PubMed ID: 15570210
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimal morphologic response to preoperative chemotherapy: an alternate outcome end point before resection of hepatic colorectal metastases.
    Shindoh J; Loyer EM; Kopetz S; Boonsirikamchai P; Maru DM; Chun YS; Zimmitti G; Curley SA; Charnsangavej C; Aloia TA; Vauthey JN
    J Clin Oncol; 2012 Dec; 30(36):4566-72. PubMed ID: 23150701
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Histological response, pattern of tumor destruction and clinical outcome after neoadjuvant chemotherapy including bevacizumab or cetuximab in patients undergoing liver resection for colorectal liver metastases.
    Stremitzer S; Stift J; Singh J; Starlinger P; Gruenberger B; Tamandl D; Gruenberger T
    Eur J Surg Oncol; 2015 Jul; 41(7):868-74. PubMed ID: 25865557
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Perioperative chemotherapy with or without bevacizumab in patients with metastatic colorectal cancer undergoing liver resection.
    Constantinidou A; Cunningham D; Shurmahi F; Asghar U; Barbachano Y; Khan A; Mudan S; Rao S; Chau I
    Clin Colorectal Cancer; 2013 Mar; 12(1):15-22. PubMed ID: 23021126
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Histopathologic evaluation of liver metastases from colorectal cancer in patients treated with FOLFOXIRI plus bevacizumab.
    Loupakis F; Schirripa M; Caparello C; Funel N; Pollina L; Vasile E; Cremolini C; Salvatore L; Morvillo M; Antoniotti C; Marmorino F; Masi G; Falcone A
    Br J Cancer; 2013 Jun; 108(12):2549-56. PubMed ID: 23703247
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preoperative chemotherapy and the risk of hepatotoxicity and morbidity after liver resection for metastatic colorectal cancer: a single institution experience.
    Wolf PS; Park JO; Bao F; Allen PJ; DeMatteo RP; Fong Y; Jarnagin WR; Kingham TP; Gönen M; Kemeny N; Shia J; D'Angelica MI
    J Am Coll Surg; 2013 Jan; 216(1):41-9. PubMed ID: 23041049
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Preoperative chemotherapy in the surgical treatment of colorectal liver metastases].
    Dede K; Láng I; Pörneczi B; Mester G; Fekete A; Kőszegi G; Mersich T; Besznyák I; Bursics A
    Magy Seb; 2013 Dec; 66(6):325-30. PubMed ID: 24333977
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized controlled trial of irinotecan drug-eluting beads with simultaneous FOLFOX and bevacizumab for patients with unresectable colorectal liver-limited metastasis.
    Martin RC; Scoggins CR; Schreeder M; Rilling WS; Laing CJ; Tatum CM; Kelly LR; Garcia-Monaco RD; Sharma VR; Crocenzi TS; Strasberg SM
    Cancer; 2015 Oct; 121(20):3649-58. PubMed ID: 26149602
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Is resection of colorectal liver metastases after a second-line chemotherapy regimen justified?
    Brouquet A; Overman MJ; Kopetz S; Maru DM; Loyer EM; Andreou A; Cooper A; Curley SA; Garrett CR; Abdalla EK; Vauthey JN
    Cancer; 2011 Oct; 117(19):4484-92. PubMed ID: 21446046
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Perioperative chemotherapy with bevacizumab and liver resection for colorectal cancer liver metastasis.
    Chaudhury P; Hassanain M; Bouganim N; Salman A; Kavan P; Metrakos P
    HPB (Oxford); 2010 Feb; 12(1):37-42. PubMed ID: 20495643
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preoperative bevacizumab does not significantly increase postoperative complication rates in patients undergoing hepatic surgery for colorectal cancer liver metastases.
    Kesmodel SB; Ellis LM; Lin E; Chang GJ; Abdalla EK; Kopetz S; Vauthey JN; Rodriguez-Bigas MA; Curley SA; Feig BW
    J Clin Oncol; 2008 Nov; 26(32):5254-60. PubMed ID: 18854565
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of bevacizumab added preoperatively to oxaliplatin on liver injury and complications after resection of colorectal liver metastases.
    van der Pool AE; Marsman HA; Verheij J; Ten Kate FJ; Eggermont AM; Ijzermans JN; Verhoef C
    J Surg Oncol; 2012 Dec; 106(7):892-7. PubMed ID: 22552819
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II trial of hepatic artery infusional and systemic chemotherapy for patients with unresectable hepatic metastases from colorectal cancer: conversion to resection and long-term outcomes.
    DʼAngelica MI; Correa-Gallego C; Paty PB; Cercek A; Gewirtz AN; Chou JF; Capanu M; Kingham TP; Fong Y; DeMatteo RP; Allen PJ; Jarnagin WR; Kemeny N
    Ann Surg; 2015 Feb; 261(2):353-60. PubMed ID: 24646562
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of chemotherapy-associated liver injury in patients with colorectal cancer liver metastases using indocyanine green clearance testing.
    Krieger PM; Tamandl D; Herberger B; Faybik P; Fleischmann E; Maresch J; Gruenberger T
    Ann Surg Oncol; 2011 Jun; 18(6):1644-50. PubMed ID: 21207168
    [TBL] [Abstract][Full Text] [Related]  

  • 18. First description of an uterine perforation potentially imputable to treatment with bevacizumab.
    Uguen T; Leconte B; Desgrippes R; Tchoundeu B; Bretagne JF; Manfredi S
    Acta Oncol; 2012 Nov; 51(8):1102-4. PubMed ID: 23020310
    [No Abstract]   [Full Text] [Related]  

  • 19. Pathologic complete response to neoadjuvant FOLFOX in combination with bevacizumab in unresectable metastatic colorectal carcinoma.
    Duffy A; Shia J; Huitzil-Melendez FD; Fong Y; O'Reilly EM
    Clin Colorectal Cancer; 2008 Mar; 7(2):140-3. PubMed ID: 18501074
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Liver resection following FOLFOXIRI plus bevacizumab: a detailed pathological review.
    Walter H; Thomas AL
    Br J Cancer; 2013 Jun; 108(12):2417-8. PubMed ID: 23801031
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.